in people of color (Asians and Blacks). 2 In some cases, one of the two could be mistaken for the other. Hypertrophic scars are usually raised, but seldom elevated 4 mm above the skin, reddish or pinkish in color, hard, pruritic, and do not extend beyond the general margins of the wound. 2 The pathogenesis of hypertrophic scars has not been fully elucidated. However, some of the factors associated with the formation of hypertrophic scars and keloids include inflammation, neural factors, cytokines, and tension. The secretion of interleukin 12 and interferon gamma have been linked to skin fibrosis which results in the development of both hypertrophic scars and keloids, whereas the secretion of cytokines (IL-4, IL-5, IL-10, and IL-13) have been linked to the development of keloids. 2, 7 Keloids behave like benign tumors 7 , they grow beyond wound margins and they can form spontaneously or as a result of a predisposing genetic disorders such as RubinsteinTaybi syndrome. 2 Keloids commonly occurs dark in skin, with higher incident rate in Africans. 8 The treatment of both hypertrophic scars and keloids still remain a challenge due to their unclear etiology.
Current treatments include surgical and nonsurgical methods such as
compression, silicone sheet, cryotherapy, laser, intralesional steroid
injections, intralesional 5-FU injections, and intralesional Botulinum
Toxin A (BoNT-A) injections. 2, 9 Intralesional BoNT-A injection is now one of the most promising methods for the prevention and treatment of hypertrophic scars and keloids.
| MECHANIS M OF AC TI ON OF BOTULIN UM TOXIN T YPE A ON HYPERTROPHIC SC AR S AND K ELOIDS
BoNT-A is one of the eight protein neurotoxins derived from anaerobic bacteria Clotridium botulinum. It works by inflexibly binding to the neuromuscular junction and therefore inhibiting presynaptic release of acetylcholine. 10, 11 BoNT-A has been used for medical purposes since in the 1980 s. 12, 13 Since then it has been widely used in treating pathological muscle contractions and autonomic hyperactivity. 14 When administered locally, BoNT-A causes temporary muscle paralysis lasting from 2 to 6 months. 15 In recent years, more physicians prefer intralesional BoNT-A as therapy of choice for prevention and treatment of hypertrophic scars and keloids. It is used as a monotherapy or in combination therapy. New medical and esthetic uses of BoNT-A have been discovered over the years, and it is still an active area of research.
The theory of the use of BoNT-A for treating pathological scars was first published in 2000. To this day, its mechanism theory is still not clearly understood. The most favorable quality of intralesional
BoNT-A is the near-complete absence of side effects such as skin atrophy and telangiectasia, 13 which may occur with the use of intralesional steroid injections. 
| BoNT-A action on wound Tension
We understand that the important key factor that determines the final cosmetic appearance of a scar is the tension that acts on the wound edges during the healing process. 16 Tension on the wound edges can directly (mechanically) and indirectly (chemically) lead to unfavorable scars. Tension that is perpendicular to the wound edges tend to mechanically pull the wound muscles and therefore distorting the normal wound healing process and therefore leading to the formation of hypertrophic scars 15 Not only that, but also genetic factors. Some genetic diseases such as Rubinstein-Taybi are known to cause keloids. 4, 18 There have been several studies that tried to prove the hypothesis that BoNT-A-induced paralysis of the wound edges thus minimizing tension vectors on the wound edges until the collagen could mature. 16 An experi- 
| BoNT-A action on cell cycle and gene expression of fibroblasts
Another theory of mechanism of BoNT-A on hypertrophic scars and keloids is the effect on cell cycle distribution of fibroblasts.
Fibroblasts hyperproliferation is one of the factors that result in hypertrophic scars and keloids. 20 BoNT-A may directly modulate the activity of fibroblast by altering apoptotic, migratory, and fibrotic pathways on pathological scars and thus improve their appearance. 20 Another experiment by Zhibo et al showed BoNT-A does act on fibroblasts directly, but the experiment did not explain how. Fibroblasts were extracted from hypertrophic scars. The experimental group was given BoNT-A, and the control group was not given BoNT-A. The results showed the significant difference in the cell cycle distribution between the two groups. 21 Not only that, but also some experiments have shown BoNT-A to have effect on gene expression of fibroblasts. Xiaoxue et al 22 conducted an experiment by using keloid fibroblasts. In the experiment, the fibroblasts treated with BoNT-A showed downregulation of some genes including transforming growth factor beta 1 gene (TGF-β1). BoNT-A also showed to influence the regulation of S100A4, VEGF, MMP-1, and PDGFA are other genes.
| BONT-A IN THE PRE VENTI ON AND TRE ATMENT OF PATHOLOG I C AL SC AR S

| Improving surgical scars and wound healing with BoNT-A
Over the years, surgeons have worked on ways to improve the cos- that received botulinum injections had significantly better scars compared to the control group. 24 The limitation of the study was that it only focused on one area of elective surgery and not traumatic wounds.
Kim et al conducted a split-scar, double-blinded, randomized trial involving postthyroidectomy patients. Each of the patients' scar was divided in half, each half received either BoNT-A or saline injection.
On the 6 months follow-up, there was statistically difference in scar appearance in all 15 patients that completed the study between the side that received BoNT-A injection and the side that received normal saline injection. 
Improved in appearance and narrow scars
No side effects first group, BoNT-A was injected directly or indirectly within 72 hours postsuture, the second group was the control. On the 1-year follow-up, the first group showed better scarring compared to the control group.
Another split-scar, double-blind randomized trial by Hu et al 27 stated that 16 patients who had undergone facial reconstructive surgery received intradermal BoNT-A injections immediately after suture on one side of the split-scar, and normal saline injection on the other side. On the 6 months follow-up, the side that received
BoNT-A injection had significantly better appearance and narrow scars compared to the control side in all 14 patients that completed the study.
| Effects of BoNT-A in Hypertrophic scars
We understand that hypertrophic scars occur mainly as a result of the tension exerted on wound edges. Tension can directly and indirectly lead to hypertrophic scars. BoNT-A works by inhibiting the release of acetylcholine in the neuromuscular junction by which indirectly causes the neuromuscular transmission, leading to muscle paralysis and thus reducing wound tension. 28 As a result of this and other mechanisms, BoNT-A can be used not only as treatment but also prevention of hypertrophic scars.
Although there are a few studies that contradict the use of
BoNT-A for the treatment of hypertrophic scars, there are also several clinical studies ( Table 2) was limited, the study can be considered successful due to the fact that none of the patients got negative results or no results.
Another prospective study was published by Elhefnawy, 29 which
reported that 20 patients with hypertrophic scars received intralesional BoNT-A injections once a month for a period of three months.
On the 6 months follow-up, the overall clinical response of the scars was assessed. Out of 20 patients, 14 had a good response and 6 had an excellent response in terms of decreased erythema, itching, and improvement in the overall appearance in the scar lesions.
| Effects of BoNT-A in Keloids
Keloids sometimes behave more like benign tumors. 9 Unlike hypertrophic scars, keloids grow beyond wound margins and can sometimes grow spontaneously. 2 And due to its benign tumor characteristics, the mechanism of action of BoNT-A on keloids is not clearly understood or conclusive. 31 There have been different theories on the mechanism of BoNT-A on keloids. Although the mechanism of intralesional BoNT-A on keloids is still debatable, its clinical effectiveness in the treatment of keloids is becoming more evident. It has been proven by different studies ( Table 3) that BoNT-A can be used for the treatment of keloids as it reduces TA B L E 2 Representative clinical studies in intralesional BoNT-A on treatment of hypertrophic scars A randomized double-blinded study conducted by Shaarawy et al 13 reported that 24 patients with keloids were divided into 2 groups. The first group was injected with intralesional BoNT-A and the second group with intralesional steroid. At the 7-month follow-up, there was improvement on both groups, but the improvement was more evident on the BoNT-A group. Three patients that received intralesional steroid injection had skin atrophy and telangiectasia. Therefore, concluded that efficacy and safety of intralesional BoNT-A to be more evident in comparison with the intralesional corticosteroid.
In another study conducted by a surgeon in Belfast described that 12 patients with keloids on different parts of the body including cheek, neck chest, and thigh, received intralesional BoNT-A injections for a period of an average 18 months. It took an average of 11 months to flatten the keloids scars. 
CO N FLI C T O F I NTE R E S T
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